Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
- The independent data monitoring committee (IDMC) recommended the continuation of the BBT-877 Phase 2a trial based on the initial clinical data from the first 20 participants dosed with the investigational product
- No safety concerns were raised based on the evaluation of the data presented at the IDMC meeting
According to IDMC's comprehensive assessment on the clinical data from the first 20 IPF patients dosed with BBT-877 or matching placebo for four weeks, the ongoing Phase 2a trial of BBT-877 will continue without any changes to the current study plans. Also, no serious treatment-emergent adverse events (TEAEs) were reported from the 20 patients enrolled in the study.
"We are highly encouraged with the positive review and recommendation from the first IDMC meeting, which will mark a significant step forward for our strong commitment to developing novel drugs for IPF patients," said
BBT-877, an experimental Autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by up to 90 percent in the first-in-human study. LPA is known to bind to cell receptors and induce various physiological activities, such as neovascularization, sclerosis, tumorigenesis, and tumor metastasis, leading to the development of various fibrotic diseases, including IPF. In
It is estimated that more than 58,000 new cases of IPF are diagnosed in the
About Bridge Biotherapeutics, Inc.
Bridge Biotherapeutics Inc., based in the
About BBT-877
BBT-877 is an orally administered autotaxin enzyme inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). During the Phase 1 Clinical trial, the experimental autotaxin inhibitor demonstrated lysophosphatidic acid (LPA) inhibition of up to 90 percent in multiple-ascending dose cohorts. Since
About Autotaxin
Autotaxin (ATX), a protein of approximately 900 amino acids discovered in the early 1990s, is an important enzyme for generating the lipid-signaling molecule, lysophosphatidic acid (LPA). Autotaxin's lysophospholipase D activity converts lysophosphatidylcholine (LPC) into LPA, which engages in signaling via LPA receptors. LPA signaling results in cell proliferation, migration, secretion of cytokines and chemokines, and reduction of cell apoptosis. Ultimately, autotaxin has a pathogenic role in processes of inflammation and fibrosis, making it an attractive drug target.
About idiopathic pulmonary fibrosis (IPF)
IPF is a rare, debilitating, and fatal lung disease which affects approximately 3 million people worldwide. The progression of IPF is variable and unpredictable. Over time, the lung function of an IPF patient gradually and irreversibly declines.
SOURCE Bridge Biotherapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Global Times: Five Principles of Peaceful Coexistence are anchor for world peace and prosperity
- Swiftcrypt Exchange Launches Cross-Border Payment Solution, Enhancing Global Transaction Convenience
- New Suggestion for Cleansing Skin: The Brand ‘YERMA’ is Launching New Trends in Skin Care
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!